Table I.
Patient demographics and number of cases demonstrating specific characteristics.
| Characteristic | Subcutaneous bortezomib (n=37 patients) | Intravenous bortezomib (n=44 patients) |
|---|---|---|
| Age, years (range) | 63 (43–85) | 64 (36–83) |
| Age ≥65 years | 15 (40.5%) | 18 (40.9%) |
| Male patients | 28 (75.7%) | 31 (70.5%) |
| Newly diagnosed patients | 35 (94.6%) | 38 (86.4%) |
| Myeloma type | ||
| IgG | 15 (40.5%) | 17 (38.6%) |
| IgA | 11 (29.7%) | 13 (29.5%) |
| IgD | 0 (0.0%) | 2 (4.5%) |
| IgM | 2 (5.4%) | 2 (4.5%) |
| Light chain | Lam5 (13.5%), kap4 (10.8%) | Lam6 (13.6%), kap4 (9.1%) |
| ISS stage | ||
| I–II | 15 (40.5%) | 17 (38.6%) |
| III | 22 (59.5%) | 27 (61.4%) |
| No. patients with lytic bone lesions | 24 (64.9%) | 29 (65.9%) |
| Serum albumin, g/l (range) | 34.3 (20–40) | 32.5 (21–38) |
| Plasma β2 microglobulin, mg/l (range) | 4.58 (2.9–23) | 5.77 (1.8–26.5) |
| No. patients using cyclophosphamide | 13 (35.1%) | 15 (34.1%) |
| Renal insufficiency | 6 (16.2%) | 9 (20.5%) |
| Diabetes | 3 (8.1%) | 5 (11.4%) |
| Diabetic neuropathy, grade 1 | 1 (2.7%) | 2 (4.5%) |
Data are presented as number of cases (percentage of total cases), or mean value (range), where indicated. Ig, immunoglobulin; ISS, International Staging System.